null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Anti-ATP7A Antibody [L60/4 (Formerly sold as S60-4)]

SKU STMA00113
Antibody Type Monoclonal
Applications WB
Applications IHC
Applications ICC/IF
Applications IP
Reactivity Human
Reactivity Mouse
Reactivity Rat
Host Species Mouse
Isotype IgG2b
€647
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

ATP7A Antibody [L60/4 (Formerly sold as S60-4)]

ATP7A Antibody [L60/4 (Formerly sold as S60-4)] is a mouse monoclonal antibody directed against ATP7A, offered by Assay Genie for research applications. Reported applications include WB, IHC, ICC/IF and IP. Reported reactivity: Human, Mouse and Rat. Supplied as IgG2b, purified by Protein G.

ATP7A, also known as copper-transporting ATPase 1, is a transmembrane P-type ATPase that plays a critical role in cellular copper homeostasis. It facilitates the export of excess intracellular copper by trafficking it into the secretory pathway for vesicular exocytosis. This function is essential for systemic copper absorption in the intestine and reabsorption in the kidney, processes that are effectively modeled in polarized epithelial systems such as Madin-Darby canine kidney (MDCK) cells. In the nervous system, ATP7A is indispensable for delivering copper to cuproenzymes involved in neurotransmitter synthesis, antioxidant defense, and mitochondrial function. Disruption of ATP7A-mediated copper transport leads to severe neurodevelopmental consequences, as seen in Menkes disease, a fatal X-linked disorder characterized by copper deficiency, neurodegeneration, and connective tissue abnormalities. Emerging research links ATP7A dysfunction to broader neurodegenerative processes. Impaired copper regulation contributes to oxidative stress, protein misfolding, and mitochondrial dysfunction—hallmarks of diseases such as Alzheimer’s and Parkinson’s. Moreover, ATP7A expression is altered in various cancers and has been associated with resistance to platinum-based chemotherapies like cisplatin and carboplatin. Given its dual role in systemic copper regulation and neuronal health, ATP7A is a promising target for therapeutic strategies aimed at restoring metal homeostasis in neurodegenerative diseases. Understanding its regulation and trafficking dynamics may unlock new avenues for intervention in copper-related neuropathologies. This antibody is also available conjugated to ATTO 390, ATTO 488, ATTO 594, APC, Biotin, FITC, HRP, PerCP and RPE. Supplied in 100 µg. For research use only; not for diagnostic or therapeutic procedures.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose